Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Revvity (RVTY)

Revvity raises 2026 guidance as Q2 revenue rises to $730 million

Positive Impact 4 of 5 guidance Written later

Revvity reported second-quarter 2026 revenue of $730 million, up from $720 million a year earlier, and GAAP EPS from continuing operations of $0.48 versus $0.47. The company raised its full-year 2026 guidance and agreed to sell its China Immunodiagnostics business for up to $200 million, a deal it expects to close by the end of 2027.

Key points

  • Q2 2026 revenue was $730 million, versus $720 million in Q2 2025; adjusted EPS from continuing operations was $1.41, versus $1.18
  • Adjusted EPS includes approximately $0.11 from tariff-related refunds, according to the filing
  • Full-year 2026 pro forma adjusted EPS guidance is $5.30-$5.40, and pro forma revenue guidance is $2.83-$2.86 billion, excluding China IDX
  • China IDX sale for up to $200 million, signed July 31, 2026; expected to close by the end of 2027, subject to conditions and regulatory approvals

The filing

CompanyRevvity (RVTY)
Form8-K, current report
Filed with the SECAug 4, 2026, 6:20 AM ET
Accession number0000031791-26-000022

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.